PURPOSE: To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Single-institution retrospective comparative outcome analysis in a cohort of 273 relapsed chemosensitive NHL patients of whom 127 (47%) received R pretransplantation. RESULTS: R was administered a median of 3 months before autologous transplantation. When compared to the nonrituximab group, R patients were older (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P = .001). Pretransplantation R did not affect stem-cell mobilization, post-transplantation early complications, duration of hospitalization, or mortality rates at days 30 and 100. In contrast to patients with low-grade NHL, both disease-free and overall survival rates were significantly better when R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL. CONCLUSION: In this large, single-center retrospective analysis, pretransplantation treatment with R was associated with improved survival in patients with intermediate-grade NHL, at the price, however, of a delay in platelet engraftment.
PURPOSE: To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Single-institution retrospective comparative outcome analysis in a cohort of 273 relapsed chemosensitive NHL patients of whom 127 (47%) received R pretransplantation. RESULTS: R was administered a median of 3 months before autologous transplantation. When compared to the nonrituximab group, R patients were older (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P = .001). Pretransplantation R did not affect stem-cell mobilization, post-transplantation early complications, duration of hospitalization, or mortality rates at days 30 and 100. In contrast to patients with low-grade NHL, both disease-free and overall survival rates were significantly better when R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL. CONCLUSION: In this large, single-center retrospective analysis, pretransplantation treatment with R was associated with improved survival in patients with intermediate-grade NHL, at the price, however, of a delay in platelet engraftment.
Authors: Douglas E Gladstone; Javier Bolaños-Meade; Carol Ann Huff; Marianna Zahurak; Ian Flinn; Ivan Borrello; Leo Luznik; Ephraim Fuchs; Yvette Kasamon; William Matsui; Jonathan Powell; Hyam Levitsky; Robert A Brodsky; Richard Ambinder; Richard J Jones; Lode J Swinnen Journal: Leuk Lymphoma Date: 2011-07-14
Authors: Thomas E Witzig; Susan M Geyer; Paul J Kurtin; Joseph P Colgan; David J Inwards; Ivana N M Micallef; Betsy R LaPlant; John C Michalak; Muhammad Salim; Robert J Dalton; Dennis F Moore; Craig B Reeder Journal: Leuk Lymphoma Date: 2008-06
Authors: Julie M Vose; Shelly Carter; Linda J Burns; Ernesto Ayala; Oliver W Press; Craig H Moskowitz; Edward A Stadtmauer; Shin Mineshi; Richard Ambinder; Timothy Fenske; Mary Horowitz; Richard Fisher; Marcie Tomblyn Journal: J Clin Oncol Date: 2013-03-11 Impact factor: 44.544
Authors: Timothy S Fenske; Parameswaran N Hari; Jeanette Carreras; Mei-Jie Zhang; Rammurti T Kamble; Brian J Bolwell; Mitchell S Cairo; Richard E Champlin; Yi-Bin Chen; César O Freytes; Robert Peter Gale; Gregory A Hale; Osman Ilhan; H Jean Khoury; John Lister; Dipnarine Maharaj; David I Marks; Reinhold Munker; Andrew L Pecora; Philip A Rowlings; Thomas C Shea; Patrick Stiff; Peter H Wiernik; Jane N Winter; J Douglas Rizzo; Koen van Besien; Hillard M Lazarus; Julie M Vose Journal: Biol Blood Marrow Transplant Date: 2009-11 Impact factor: 5.742